Anil Rajendra1, Tina D Hunter2, Gustavo X Morales3, Paul Zei4, Lee Ming Boo5, Allyson Varley6, Jose Osorio3. 1. Alabama Cardiovascular Group, Suite 720, Birmingham, AL, 3686, USA. arajendra@alcardio.com. 2. CTI Clinical Trial Services, Covington, KY, USA. 3. Alabama Cardiovascular Group, Suite 720, Birmingham, AL, 3686, USA. 4. Brigham and Women's Hospital, Boston, MA, USA. 5. Biosense Webster, Inc, Irvine, CA, USA. 6. Heart Rhythm Clinical and Research Solutions, Birmingham, AL, USA.
Abstract
BACKGROUND: Advances in technology and workflows have facilitated substantial reductions in fluoroscopy utilization and procedure times for atrial fibrillation (AF) ablations. A recently available steerable sheath, visualizable on a 3D electroanatomical map (EAM), may further simplify low/zero fluoroscopy ablation workflows by facilitating understanding of the relative positions of the catheter and sheath. The objective of this study was to demonstrate feasibility, safety, procedural efficiency, and clinical effectiveness of incorporating the new visualizable sheath into a low-fluoroscopy workflow. METHODS: Consecutive de novo paroxysmal AF procedures were performed with a porous tip contact force catheter at a high-volume site between January 2018 and May 2019. Procedures performed with and without the VIZIGO™ EAM-visualizable sheath (Vizigo) were compared. All ablations employed the same standardized low-fluoroscopy workflow. Statistical analyses employed stabilized inverse probability of treatment weights (IPTW) to balance cohorts by operator and key patient characteristics. RESULTS: Cohorts of 142 Vizigo and 173 non-Vizigo patients were similar at baseline. Use of the Vizigo sheath was associated with approximately 10% improvement in catheter stability (p = 0.0005), 16% reduction in radiofrequency time (p < 0.0001), and 7% fewer ablations that used fluoroscopy (p = 0.0030). There was one cardiac tamponade in each cohort and no deaths, atrioesophageal fistulas, or strokes. Single-procedure freedom from atrial arrhythmia recurrence through 12 months was similar between cohorts (p = 0.9556). CONCLUSIONS: Use of a 3D EAM-visualizable sheath resulted in improved catheter stability, reduced radiofrequency time, and more procedures performed without fluoroscopy, without compromise to safety or effectiveness.
BACKGROUND: Advances in technology and workflows have facilitated substantial reductions in fluoroscopy utilization and procedure times for atrial fibrillation (AF) ablations. A recently available steerable sheath, visualizable on a 3D electroanatomical map (EAM), may further simplify low/zero fluoroscopy ablation workflows by facilitating understanding of the relative positions of the catheter and sheath. The objective of this study was to demonstrate feasibility, safety, procedural efficiency, and clinical effectiveness of incorporating the new visualizable sheath into a low-fluoroscopy workflow. METHODS: Consecutive de novo paroxysmal AF procedures were performed with a porous tip contact force catheter at a high-volume site between January 2018 and May 2019. Procedures performed with and without the VIZIGO™ EAM-visualizable sheath (Vizigo) were compared. All ablations employed the same standardized low-fluoroscopy workflow. Statistical analyses employed stabilized inverse probability of treatment weights (IPTW) to balance cohorts by operator and key patient characteristics. RESULTS: Cohorts of 142 Vizigo and 173 non-Vizigo patients were similar at baseline. Use of the Vizigo sheath was associated with approximately 10% improvement in catheter stability (p = 0.0005), 16% reduction in radiofrequency time (p < 0.0001), and 7% fewer ablations that used fluoroscopy (p = 0.0030). There was one cardiac tamponade in each cohort and no deaths, atrioesophageal fistulas, or strokes. Single-procedure freedom from atrial arrhythmia recurrence through 12 months was similar between cohorts (p = 0.9556). CONCLUSIONS: Use of a 3D EAM-visualizable sheath resulted in improved catheter stability, reduced radiofrequency time, and more procedures performed without fluoroscopy, without compromise to safety or effectiveness.
Authors: Li Yang; Ge Sun; Xiaomei Chen; Guangzhi Chen; Shanshan Yang; Ping Guo; Yan Wang; Dao Wen Wang Journal: Am J Cardiol Date: 2016-08-24 Impact factor: 2.778
Authors: Christopher Piorkowski; Charlotte Eitel; Sascha Rolf; Kerstin Bode; Philipp Sommer; Thomas Gaspar; Simon Kircher; Ulrike Wetzel; Abdul Shokor Parwani; Leif-Hendrik Boldt; Meinhard Mende; Andreas Bollmann; Daniela Husser; Nikolaos Dagres; Masahiro Esato; Arash Arya; Wilhelm Haverkamp; Gerhard Hindricks Journal: Circ Arrhythm Electrophysiol Date: 2011-01-19
Authors: Ugur Canpolat; Michela Faggioni; Domenico G Della Rocca; Qiong Chen; Huseyin Ayhan; Andrew A Vu; Sanghamitra Mohanty; Chintan Trivedi; Carola Gianni; Mohammed Bassiouny; Amin Al-Ahmad; J David Burkhardt; Javier E Sanchez; G Joseph Gallinghouse; Andrea Natale; Rodney P Horton Journal: J Innov Card Rhythm Manag Date: 2020-03-15